Here’s what to expect from Abbott’s Q2 earnings

Abbott Laboratories (NYSE:ABT) is scheduled to announce Q2 earnings results on Thursday, July 17th, before market open.

Analysts expect continued growth, with consensus estimates calling for EPS of $1.26, up 10.5% year-over-year, and revenue of $11.06 billion, reflecting a 6.3% annual increase.

The company has a strong track record of exceeding expectations—beating EPS estimates in 88% of the last eight quarters and revenue estimates in 75% of those periods.

Analyst sentiment has been mostly positive ahead of the release. Over the past three months, EPS estimates have seen 9 upward revisions and 7 downward, while revenue estimates have been revised upward 15 times versus 3 downward revisions.

Investors will be watching for updates on Abbott’s medical devices segment, which has driven recent growth, as well as any commentary on emerging markets, innovation in diagnostics, and the broader healthcare spending environment.

“Abbott remains a solid, strategic healthcare holding – well-positioned for steady growth, with risks managed. Management’s focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policies like dividend increases support long-term value,” said SA columnist Larry Hall.